0.0922

1.73% 0.0002

Lyra Therapeutics Inc (LYRA)

Overview News Price History Option Chain Financials Discussions Forecast

Lyra Therapeutics Inc stock is traded at $0.0922, with a volume of 714.11K. It is up +1.73% in the last 24 hours and up +1.51% over the past month. Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

Previous Close:

$0.0924

Open:

$0.09

24h Volume:

714.11K

Relative Volume:

0.23

Market Cap:

$6.06M

Revenue:

$1.47M

Net Income/Loss:

$-97.61M

P/E Ratio:

-0.0619

EPS:

-1.49

Net Cash Flow:

$-80.90M

1W Performance:

-15.85%

1M Performance:

+1.51%

6M Performance:

-50.26%

1Y Performance:

-71.17%

1-Day Range:

$0.088

$0.0968

1-Week Range:

$0.0844

$0.1149

52-Week Range:

$0.082

$0.344

Lyra Therapeutics Inc Stock (LYRA) Company Profile

Name

Lyra Therapeutics Inc

Sector

Healthcare (1178)

Industry

Biotechnology (668)

Phone

617-373-4600

Address

480 ARSENAL WAY, WATERTOWN, MA

Employee

Twitter

@LyraTx

Next Earnings Date

2025-03-12

Latest SEC Filings

LYRA's Discussions on Twitter

Compare LYRA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LYRA Lyra Therapeutics Inc	0.0914	7.47M	1.47M	-97.61M	-80.90M	-1.49
ONC Beigene Ltd Adr	242.08	24.41B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	436.23	111.55B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.31	42.47M	0	0	0	0.00
REGN Regeneron Pharmaceuticals Inc	588.27	63.16B	14.09B	4.50B	2.96B	39.28
VRNA Verona Pharma Plc Adr	75.13	5.92B	0	-153.72M	-103.81M	-2.00

Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-07-24	Downgrade	BofA Securities	Buy → Underperform
May-07-24	Downgrade	H.C. Wainwright	Buy → Neutral
May-07-24	Downgrade	Jefferies	Buy → Hold
May-06-24	Downgrade	William Blair	Outperform → Mkt Perform
Oct-06-23	Resumed	BTIG Research	Buy
Aug-31-23	Initiated	H.C. Wainwright	Buy
May-24-22	Initiated	Cantor Fitzgerald	Overweight
May-26-20	Initiated	BTIG Research	Buy
May-26-20	Initiated	BofA/Merrill	Buy
May-26-20	Initiated	Jefferies	Buy
May-26-20	Initiated	William Blair	Outperform

View All

Lyra Therapeutics Inc Stock (LYRA) Latest News

May 22, 2025

Petri Dish: Thermo Fisher’s new partner; Waters buys California company - The Business Journals

May 22, 2025

May 20, 2025

Pre-market Movers: NRXS, EYEN, TIL, HCTI, EKSO... - RTTNews

May 20, 2025

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

May 20, 2025

US Stocks Likely To Open Lower After S&P 500's Six-Day Streak: 'Quick Recoveries Tend To See Stocks Rally More Over The Next 3-12 Months,' Says ExpertASP Isotopes (NASDAQ:ASPI) - Benzinga

May 20, 2025

Why Pegasystems Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket - Benzinga

May 20, 2025

May 19, 2025

JPMorgan Chase & Co. Has $32,000 Stake in Lyra Therapeutics, Inc. (NASDAQ:LYRA) - Defense World

May 08, 2025

JPMorgan Chase & Co. Has $40,000 Stake in Tevogen Bio Holdings Inc. (NASDAQ:TVGN) - Defense World

May 08, 2025

May 07, 2025

Lyra Therapeutics to Present 52-Week Extension Stage Results for Enlighten 1 Phase 3 Study for Lyr-210 for the Treatment of Chronic Rhinosinusitis At Cosm 2025 - marketscreener.com

May 07, 2025

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times

May 07, 2025

Lyra Therapeutics Reports Positive Safety and Efficacy Results for LYR-210 in Phase 3 Extension Study for Chronic Rhinosinusitis - Nasdaq

May 07, 2025

Lyra Therapeutics to Present 52-week Extension Stage - GlobeNewswire

May 07, 2025

Lyra Therapeutics Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView

May 07, 2025

Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025 - GlobeNewswire Inc.

May 07, 2025

May 06, 2025

Lyra Therapeutics, Inc. (NASDAQ:LYRA) Receives $1.25 Consensus Target Price from Analysts - Defense World

May 06, 2025

Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times

May 06, 2025

Lyra Therapeutics Nears Critical Phase 3 Results for Revolutionary CRS Treatment as Q1 Losses Narrow 62% - Stock Titan

May 06, 2025

May 04, 2025

JPMorgan Chase & Co. Boosts Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World

May 04, 2025

Geode Capital Management LLC Has $183,000 Stock Position in Lyra Therapeutics, Inc. (NASDAQ:LYRA) - Defense World

May 04, 2025

Ascendiant Capital Markets Predicts VMAR Q1 Earnings - Defense World

May 04, 2025

Apr 30, 2025